Recently, the national epidemic policy has continued to relax, and localities have no longer registered and restricted to buy cold medicines and antipyretics, and the wind of residents' hoarding of medicines.
On December 6, the era of oak commercial visits to dozens of pharmacies in Wuhan found that even cold medicines and antipyretic medicines such as Qinghua and ibuprofen were swept away.
Even domestic pharmaceuticals and retail giants such as Kyushu and the people, and offline pharmacies are facing out of stock.
At the same time, speculators and speculators have also entered the venue.
On the e -commerce platform, a pharmacy increased the original price of 30 yuan/box to the Lianhua Qing Plague 0.35g*48 capsules to 102 yuan/box, an increase of 240%year -on -year.
The capital market moved.
Lianhua Qing Plague manufacturer Yi Ling Pharmaceutical (002603) today exceeded 10 billion yuan in stock turnover, refreshing historical records; while the recent A -share turnover exceeded 10 billion, Guizhou Maotai.
The main components of Lianhua Qing Plague are forsythia, honeysuckle, and developed in the SARS period.
Wu Yiling, the founder of Yiling Pharmaceutical, introduced Lianhua Qing Plague: In March 2003, Beijing received the first SARS case, and he quickly led the team to open a new drug research and development.The production of even flowers Qing Plague; 347 days later, Lianhua Qingjuan, as an innovative patent traditional Chinese medicine for popular colds, was allowed to produce and listed.
At the beginning of the outbreak of the new crown epidemic in 2020, even the flowers of the flowers were incorporated into the diagnosis and treatment plan, and they were widely used in the treatment of the new crown. In April this year, the adaptation of the flowers of the flowers was approved to increase the treatment of the new crown.
Lianhua Qing Plague became a magic medicine, and rushed with Yiling Pharmaceutical's stock price.
In 2020, the sales revenue was 4.256 billion yuan, a year -on -year increase of 149.89%; sales in the first three quarters of 2021 exceeded 3 billion.
The stock price of Ling Pharmaceutical's stock rose from 12 yuan to 44 yuan within three years.
In April this year, the Forbes Rich List announced that the 73 -year -old Wu Yiling was worth $ 1.5 billion (10.4 billion yuan) to become the richest man in China.
However, in addition to capital and wealth, the effectiveness of the new crown of flowers in the flowers has always been questioned in the academic community.
One: Pay money with Ling Pharmaceuticals, Academician and son -in -law do experiments, concluded: safety, effective
In May 2020, Academician Zhang Boli, Academician Li Lanjuan, Academician Zhong Nanshan, and Dean Jia Zhenhua of Hebei Emidei Hospital as a communicator, published a clinical clinical test of the new crowned efficacy test of the new crowns on PHYTOMEDICINE.Research papers, thesis conclusions: Lianhua Qing Plague is effective and safe for the treatment of new crown pneumonia
The paper was cited by individual academic people to demonstrate the effectiveness of even the new crown of the flowers of the flowers; it was also one of the important basis for the approved to increase the treatment of the new crown.
It is worth noting that when the paper was initially published, neither Jia Zhenhua nor Zhong Nanshan did not make a conflict of interest.
Until a year later, in October 2021, someone reported the paper to plant medicine. Under the requirements of plant medicine, the author added the corresponding statement:
1. Jia Zhenhua, born in 1975, is the son -in -law of Wu Yiling, the founder of Yiling Pharmaceutical;
2. This research part has been funded by Shijiazhuang Yiling Pharmaceutical Group (about 10.4%of research funds)
There are still omissions in this statement.
According to November 2021, another correction material involved in the conflict of interest in the Lianhua Qing Plague Research showed that Zhong Nanshan and Shijiazhuang Iso Ling Pharmaceutical Group signed a cooperation project agreement in 2015.
It is unclear this cooperation agreement. On July 26, 2019, Wu Yiling went to the Yuexiu Campus of Guangzhou Medical University to cut the ribbon with the Nanshan-Yiling Lungluo Research Center with Zhong Nanshan.
And from 2020, Zhong Nanshan has repeatedly said in public: Lianhua Qing Plague is really effective.
It is called by the media as a supporter and a consignee of the Lianhua Qing Plague.
Two: Academic criticism: Academic research needs to be neutral
Immuni scholar Shang Zhou criticized the above thesis in intellectuals: academic research needs to be neutral, so researchers need to declare conflicts of interest when publishing papers, which is a practice in the academic community.
And the Shang and Zhou Dynasties kept questioning the final conclusion of the paper:
1. In the experiment of the thesis, the two groups of new crown patients (one group of flowers clearing the plague and one group did not) have a small difference in the final recovery rate.
2. Most of the patients in the project are mild disease, no torture, and no basic disease.
3. This research is an open-label trial, not a double-blind trial, that is, doctors and patients know who has taken Lianhua Qing plague.
Yin Guosheng, director of the Department of Statistics and Ectulation of the University of Hong Kong and Professor Pan Yichang Fund, pointed out that even the effectiveness of the flowers of the flowers still requires strict double -blind randomly controlled clinical trials to further verify.
If it is not a double -blind experiment, it is not worthy of reference, even the flowers of the flowers have double -blind experiments?
Caixin has statistics that there are only two experiments on the new crown of the Lianhua Qing Plague as a double blind: one experiment has not ended at Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College;Not yet started.
In addition to paradoxical experiments, even Huaqing Plague was repeatedly questioned and blocked abroad.
The Singapore Health Science Bureau (HSA) once said that even the flowers of the flowers of the flowers are registered as a Chineseopathy, referring to the auxiliary health products that can be sold by the authorities, and cannot be used to diagnose or treat infectious diseases.
Swedish Customs prohibits even flowers from entering the customs. It is believed that the most active ingredients are mint alcohol (reports of Chinese media are generally that components only contain mint), and they do not recognize that they are effective in the treatment of new crowns.
As early as mid -2020, the Australian Border Law Enforcement (ABF) has warned the people that the people have been detained in the United States and Canada Customs because they contain ephedra that contains ephedra.
In the United States, in December 2015, Lianhua Qing Plague Capsule was approved by the US FDA to conduct a second phase of clinical research, becoming the world's first compound cure anti -influenza Chinese medicine in the United States to enter the FDA clinical research.
But 6 years have passed, and the results of the study have not been disclosed.
